Skip to main content
. 2022 Dec 12;10(12):3225. doi: 10.3390/biomedicines10123225

Figure 3.

Figure 3

Comparing pretreatment HNSCC (n = 53) and combined control subjects (n = 40) for TIMP-1 and Hsp70 both in serum and saliva. (a) TIMP-1 saliva concentration in HNSCC and combined control subjects; (b) Hsp70 saliva concentration in HNSCC and combined control subjects; (c) TIMP-1/Hsp70 saliva ratio comparing HNSCC and combined control subjects; (d) saliva TIMP-1 in smokers with HNSCC and combined smoking control subjects; (e) saliva Hsp70 in smokers with HNSCC and combined smoking control subjects; and (f) TIMP-1/Hsp70 ratio in smokers with HNSCC and combined smoking control subjects.